Graft Versus Host Disease Pipeline
Oct 18, 2019
Incyte Corporation submits positive results of trials for its drug Ruxolitinib in GvHD
Incyte Corporation has recently announced the results of Novartis-sponsored Phase III clinical trials REACH2 evaluating its candidate Ruxolitinib (Jakafi) in patients suffering from steroid-refractory acute graft-versus-host disease (GvHD). Graft versus host disease (GvHD), as defined by the National Cancer Institu...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
